This is of particular interest because, while the PIP5K1C inhibitor UNC3230 is not approved for the use in breast cancer, AKT inhibitors like the pan-AKT inhibitor capivasertib have previously shown promising results in clinical trials on breast cancer patients [34–36]. This evidence concerns the gene AKT1 and breast carcinoma.